Doug Johnson
Vorstandsvorsitzender bei Canfund Ventures Corp.
Vermögen: 751 400 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Anthony Ker | M | 67 | 16 Jahre | |
| David Dreisinger | M | 65 | 15 Jahre | |
| Mike Rudd | M | - |
Pathfinder Asset Management Ltd. (Canada)
 Pathfinder Asset Management Ltd. (Canada) Investment ManagersFinance Pathfinder Asset Management Ltd. (Pathfinder) is an independent, employee-owned investment management firm headquartered in Vancouver, Canada. The firm was founded by Douglas B. Johnson in 2010. Pathfinder manages a custom portfolio for high-net-worth investors who seek strong performance and risk-managed results. | 13 Jahre |
| Christian James Anthony | M | - |
Pathfinder Asset Management Ltd. (Canada)
Pathfinder Asset Management Ltd. (Canada) Investment ManagersFinance Pathfinder Asset Management Ltd. (Pathfinder) is an independent, employee-owned investment management firm headquartered in Vancouver, Canada. The firm was founded by Douglas B. Johnson in 2010. Pathfinder manages a custom portfolio for high-net-worth investors who seek strong performance and risk-managed results. | 11 Jahre |
| Matthew Anderson | M | 41 | 14 Jahre | |
| Gary Sidhu | M | - |
Pathfinder Asset Management Ltd. (Canada)
Pathfinder Asset Management Ltd. (Canada) Investment ManagersFinance Pathfinder Asset Management Ltd. (Pathfinder) is an independent, employee-owned investment management firm headquartered in Vancouver, Canada. The firm was founded by Douglas B. Johnson in 2010. Pathfinder manages a custom portfolio for high-net-worth investors who seek strong performance and risk-managed results. | 5 Jahre |
| Mark Ouellette | M | - |
Pathfinder Asset Management Ltd. (Canada)
Pathfinder Asset Management Ltd. (Canada) Investment ManagersFinance Pathfinder Asset Management Ltd. (Pathfinder) is an independent, employee-owned investment management firm headquartered in Vancouver, Canada. The firm was founded by Douglas B. Johnson in 2010. Pathfinder manages a custom portfolio for high-net-worth investors who seek strong performance and risk-managed results. | - |
| Robert William Ballard | M | - |
Pathfinder Asset Management Ltd. (Canada)
Pathfinder Asset Management Ltd. (Canada) Investment ManagersFinance Pathfinder Asset Management Ltd. (Pathfinder) is an independent, employee-owned investment management firm headquartered in Vancouver, Canada. The firm was founded by Douglas B. Johnson in 2010. Pathfinder manages a custom portfolio for high-net-worth investors who seek strong performance and risk-managed results. | 12 Jahre |
| Fang Zhou | M | - |
Pathfinder Asset Management Ltd. (Canada)
Pathfinder Asset Management Ltd. (Canada) Investment ManagersFinance Pathfinder Asset Management Ltd. (Pathfinder) is an independent, employee-owned investment management firm headquartered in Vancouver, Canada. The firm was founded by Douglas B. Johnson in 2010. Pathfinder manages a custom portfolio for high-net-worth investors who seek strong performance and risk-managed results. | 11 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| James David Clucas | M | 82 | 9 Jahre | |
| James DeMesa | M | 66 |
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 Jahre |
| Dennis Danzik | M | - | - | |
| Kevin M. Bridges | M | 58 | - | |
| Brian E. Straub | M | - | 2 Jahre | |
| Jody J. Stachiw | M | - | 3 Jahre | |
| Bruce A. Schmidt | M | 68 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Brad Shybunka | M | - | 10 Jahre | |
| Kelly D. Sledz | M | - | 4 Jahre | |
| AnnKatrin Petersen-Jappelli | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 4 Jahre |
| James Matthew Patterson | M | 82 | 9 Jahre | |
| Raymond James Saunders | M | - | 9 Jahre | |
| Tyler Heathcote | M | - | 4 Jahre | |
| Richard Gagnon | M | - | - | |
| Richard Carrigan | M | - | 2 Jahre | |
| Pieter Dorsman | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Andrew J. Rae | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Robert Raymond | M | - | 3 Jahre | |
| Sharon Leigh Lewis | F | 80 | 1 Jahre | |
| James Curtis Yeager | M | - | 1 Jahre | |
| Steven Gillis | M | 71 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 12 Jahre |
| Paul Brennan | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 1 Jahre |
| C. Robert Cory | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 15 Jahre |
| K. David Campagnari | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 8 Jahre |
| Geir Liland | M | 74 | 3 Jahre | |
| Jim Maldaner | M | - | 1 Jahre | |
| William D. Milligan | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 Jahre |
| Jacob J. Clement | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 Jahre |
| Alistair Duncan | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 6 Jahre |
| Francis David Duke Scott | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 8 Jahre |
| Michael Jeffrey Abrams | M | 68 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Colin R. Mallet | M | 80 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 13 Jahre |
| Richard Winterich | M | - | 1 Jahre | |
| John Longley | M | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Kanada | 43 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Doug Johnson
- Persönliches Netzwerk
